ABSTRACT
This special issue contains 8 articles that explore various latest research on COVID-19, including the clinical presentation of the disease, the role of inflammation, the development of new treatments, and the long-term effects of the infection. The topics covered include the evaluation of white blood cell parameters and their significance in COVID-19 patients in Western Maharashtra, India;the association between acute phase reactants and COVID-19 severity and mortality in a tertiary care hospital in India;the clinico-hematological profile of COVID-19 patients from an Indian perspective;the correlation between C-reactive protein test results and clinical characteristics in COVID-19 patients;the effective binding affinity of an inhibitor against the SARS-CoV-2 NSP13 helicase;the assessment of absolute neutrophil count in COVID-19 patients in a tertiary care hospital;the analysis of the anti-SARS-CoV-2 IgG response following the first and second dose of a COVID-19 vaccine;and a case report discussing the diagnostic dilemma of hypoplastic acute myeloid leukemia in a COVID-19 patient.
ABSTRACT
Objective To investigate the dynamic changes of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) specific antibody IgG positive rate in coronavirus disease 2019 (COVID-19) survivors in China. Methods the relevant literatures about the positive rate of SARS-COV-2 specific antibody IgG in COVID-19 survivors in China were retrieved from PubMed, Embase, CNKI, Wanfang database and VIP database from December 2019 to February 24, 2022. The quality of the documents were assessed according the revised AHRQ (Agency for Healthcare Research and Quality) statement. Freeman-tukey double arsinusoidal conversion method was used to calculate the positive rate, and StataSE15.0 software was used for statistical analysis. Subgroup analysis was performed according to detection method and fragment, and publication bias was examined by Egger method. Results A total of 12 articles were included, IgG was detected from the first month to the twelfth month after SARS-COV-2 infection, and the total sample size ranged from 74 to 2 907 cases per month. The positive rate was the highest in the second month and the third month, 96.35% (95% CI: 93.98%-98.14%) and 97.23% (95% CI: 94.47%-99.05%) respectively. The positive rate decreased gradually with time, and reached 73.63% (95% CI: 50.31%-91.45%) in the twelfth month. The results of subgroup analysis showed that the heterogeneity between studies with the different detection method and the different detection fragment were significant differences (X2=5.02-39.57, all P < 0.05). Egger method test published bias, and the difference was not statistically significant (t=1.85, P=0.101). Conclusion Most people, one year after infection with SARSCOV- 2, could still detect SARS-COV-2 specific antibody IgG.
ABSTRACT
ObjectiveTo investigate the specific anti-SARS-CoV-2 antibody in adults and above after initial vaccination with inactivated COVID-19 vaccine, and determine the influencing factors. MethodsIn this study, residents aged 18 and above who had completed two doses of inactivated COVID-19 vaccine in Deqing County, Huzhou City, Zhejiang Province were included. Information such as gender, age, type of vaccine and vaccination time were collected, and serum specimens were sampled. Anti-SARS-CoV-2 receptor binding domain (RBD) antibody was quantitatively examined by enzyma-linked immunosorbent assay (ELISA) and influencing factors were determined. ResultsThe median concentration of anti-SARS-CoV-2 IgG antibody in the residents vaccinated with an inactivated booster vaccine was higher than that in those vaccinated with only two doses of COVID-19 vaccine or single dose (P<0.05). The median concentration of IgG antibody in males was 9.73 (4.01-23.70) RUmL-1, lower than 17.76 (7.07-49.23) RUmL-1 in females (P<0.05). The median concentration in the residents vaccinated with BBIBP-CorV (Sinopharm) was 6.53 (0.97-13.69) RUmL-1, which was lower than that in those vaccinated with CoronaVac (Sinovac) that was 17.29 (8.54-43.73) RUmL-1 (P<0.05). The median concentration in those with BBIBP-CorV was also lower than 12 (5.45-40.06) RUmL-1 in those with heterologous booster vaccine (P<0.05). The median concentration was 9.73 (3.83-23.63) RUmL-1 in the residents with an interval of more than 6 months from the second dose, which was lower than 14.66 (6.36-35.98) RUmL-1 in those with an interval of 3-6 months (P<0.05). Moreover, immune effect was better in females (X2=16.464, P<0.05), 18-45 years (X2=7.158, P<0.05), and those vaccinated with CornaVac (X2=49.637, P<0.05), while decreased in those with an interval of more than 6 months from the second dose (X2=8.447, P<0.05). ConclusionGender, age, and type of vaccine may affect the effect of immunization. The COVID-19 vaccination shows an acceptable immunogenicity in adults;however, it declines in 6 months after vaccination. It warrants strengthening the booster vaccination to maintain the immune response.
ABSTRACT
Objective: Since the resumption of face-to-face education in October 2020, which was suspended due to the COVID-19 pandemic, coincides with the period when SARS-CoV-2 infection rates in young adults are on the rise. This study focuses on the 2019 corona virus outbreak in young adults, the largest link in the chain of transmission, which can be defined as silent contagious agents. It is aimed to provide epidemiological data by detecting virus disease (COVID-19) seropositivity with two different serological methods, and to evaluate the symptom-test performance relationship of asymptomatic/mild symptom/symptomatic cases. Methods: A cross-sectional study was conducted with students studying at Cappadocia University health programs between December 2020 and February 2021 and who will attend practice courses face-to-face. Participants were surveyed about their COVID-19 symptoms and disease histories based on SARS-CoV-2 exposure. For SARS-CoV-2 antibody detection, blood samples were taken from the participants and investigated with a single lateral flow immunoAssay (LFIA, Novatech, Turkey) cassette test. The samples with positive test result were then SARS-CoV-2 Anti-N IgM+IgG;SARS-CoV-2 Anti-S IgM+IgG;SARS-CoV-2 Anti-RBD IgG;It was re-evaluated using the electrochemiluminescence immunoassay (ECLIA) method with the anti-SARS-CoV-2 kit (Roche, Germany). Results: Of the 239 samples participating in the study, 50 (20.9%) samples that were positive for SARS-CoV2 IgM/ IgG according to the LFIA method were then studied again with the ECLIA method. According to the ECLIA result, 72% (36/50) of individuals against both nucleocapsid (N) and spike (S) antigens, and 70% (35) against RBD antigen were seropositive. Based on the ECLIA test results, 239 samples were studied and 50 samples were found to be IgM/IgG positive, with a sensitivity of 64% and a specificity of 93%. Contingence history was reported in 46% (n=23) of patients who were seropositive by both methods, while 30% (n=15) showed a COVID-19 clinic. Fifty four percent (n=27) of the participants reported that they did not have a PCR (polymerase chain reaction) test, but antibody response was observed in all of them. Only 28% (n=14) of seropositive patients reported positive PCR results, and 4% of them stated that they had a chronic disease. It will be important to continue to observe the serological status of young people, particularly in the context of new COVID-19 variants and in the low interest in mass vaccination campaigns targeting young people. Conclusion: It is thought that the performance of ECLIA with rapid casette test does not have a good degree of agreement and confirmation with different immunoassay tests would be more useful for epidemiological surveillance. Especially the new COVID-19 in the context of the variants and targeting youth due to the lack of interest in vaccination champaigns continue to monitor the serological status of young people it will be important.
ABSTRACT
The recent vaccination campaign targeting the new coronavirus infection (COVID-19) carried out in the Armed Forces of the Russian Federation, on the background of the current unstable global pandemic situation, makes it necessary to study post-vaccination population immunity to the SARS-CoV-2 virus and thus identify key features of immunity in organized military collectives. In the future, this will make it possible to objectively assess the risks of a worsening pandemic situation, effectively adjust the ongoing sanitary and anti-epidemic measures aimed at preserving and strengthening the health of military personnel, as one of the main conditions for maintaining the combat readiness of the Armed Forces of the Russian Federation. During a study conducted on epidemic indications, it was found that vaccination with Gam-Covid-Vac contributes to the formation of collective immunity with 95% effectiveness. A gender-based analysis of the immune response showed that the proportion of persons who lack class G immunoglobulins to SARS-CoV-2 among females is twice than that among men (9.3% and 4.7%, respectively). Seroprevalence indicators, classified by blood group, range from 94.4% (AB (IV) Rh-) to 97.4% (A (II) Rh-). There were no significant differences in seroprevalence between groups of people with different blood groups;however, the highest value of seroprevalence was seen among military personnel with blood group A (II) Rh-. In this context, it is advisable to continue monitoring the formation of immunity in individuals with various blood groups. The results obtained made it possible to form a primary medical and social "portrait" of a serviceman with the most adequate immune response to the introduction of the Gam-Covid-Vac vaccine (a man under the age of 20 with blood type A (II) Rh-) and to draw a conclusion about the high effectiveness of vaccination in military units (formations) staffed by conscripts and military educational organizations.
ABSTRACT
The detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during wastewater treatment leads to concerns about whether this process may represent a focal point for the transmission of COVID-19. An epidemiological analysis, based on a COVID-19 IgG/IgM Rapid Test Cassette, performed on 134 wastewater workers from 59 wastewater treatment plants from the province of Granada (Spain) showed a seroprevalence of 8.95% in IgG for SARS-CoV-2, which is similar to the incidence rate found for the general population of the province (9.6%;95%CI = 7.2-12.8). These findings suggest that current safety measures are sufficient for the protection of workers against SARS-CoV-2.
ABSTRACT
OBJECTIVE: To investigate the immune antibodies in blood specimens of 95 health care workers vaccinated with inactivated 2019-nCoV vaccines and explore the rules and characteristics of production of antibodies after vaccination. METHODS: From Oct 2020 to Jul 2021, the venous blood specimens were collected from 95 health care workers of the 305 Hospital of PLA after the injection of 2 doses of 2019-nCoV vaccines fo30 days, 65 days, 91 days, 6 months and 9 months. SARS-CoV-2 immunoglobin(Ig) M, IgG and titers of neutralizing antibodies and total antibodies were detected by chemiluminescence immunoassay, the results of antibody tests were dynamically analyzed, the immune durability of the antibody, influencing factors and correlation were determined. RESULTS: Almost all of the subjects produced IgG, neutralizing antibody and total antibody, some subjects retained high level of IgM titer. Smoking could affect the production of total antibody. The subjects of the low body weight group produced higher level of IgG, and there was no significant difference when the weight was over 60 kg. The titers of the four types of antibodies decreased significantly at the following time points, and the positive rates of all the antibodies were less than 50% except for IgG after the vaccination for 9 months. CONCLUSION: Specific IgM and IgG, neutralizing antibody and total antibody can be produced after the 2-doses vaccination of inactivated 2019-nCoV vaccines. But the titers and positive rates of the antibodies decrease with time, which means the protective effects on the body decrease. Therefore, in order to improve the autoimmunity against novel coronavirus, one booster vaccination of an inactivated 2019-nCoV vaccine will be necessary after the 2 doses of vaccination for 6 months.
ABSTRACT
Objective: To study the changed trend of IgM and IgG specific antibody with chemiluminescent immunoassay (CLIA) and RT-PCR in SARS-CoV-2 infection patients during hospitalization. Methods: A total of 100 hospitalized patients with SARS-CoV-2 infection who admitted to the First People's Hospital of Zhaoqing were divided into vaccinated group and unvaccinated group according to whether they were vaccinated COVID-19 vaccine or not. The unvaccinated group was further divided into severe, normal, mild and asymptomatic groups. The nucleic acid test results, the positive rate of IgM and IgG antibodies measured by CLIA, and the dynamic trend of S/CO values of all SARS-CoV-2 infected patients since admission 0-<8 days, 8-<15 days, 15-<22 days, 22-<29 days, 29-<36 days and36 days were monitored, and the statistical differences between different groups were compared. Results: The positive rate of IgM antibody in the unvaccinated group 55.6% (15/27) and 0 (0/27) were all significantly higher than that in the vaccinated group 68.5% (50/73) and 49.0% (36/73) at 8-<15 days and 36 days of hospitalization (X2=11.048, 20.805, P < 0.05). The positive rate of IgG antibody in the vaccinated group 96.3% (26/27) and 100% (27/27) were all significantly higher than that in the unvaccinated group 45.2% (31/73) and 78.1% (57/73) at 0-< 8 days and 8-<15 days of hospitalization (X2=21.268, 7.576, P < 0.05). The positive rate of RNA in the unvaccinated were all significantly higher than that in the vaccinated group at 8-<15 days 76.7% (56/73) and 29.6% (8/27), 15-<22 days 65.8% (48/73) and 14.8% (4/27), 22-<29 days 42.5%(31/73) and 7.4% (2/27), 29~<36 days 26.0% (19/73) and 7.4% (2/27) of hospitalization (X2=18.694,20.490, 10.957, 4.119, all P < 0.05). The S/CO value of IgG antibody in the vaccinated group were all significantly higher than that in the unvaccinated group at differentperiods of hospitalization (t=2.841, 7.135, all P < 0.05), but there was no significant difference in the S/CO value of IgM antibodyat different periods of hospitalization in pairwise comparison (P > 0.05). The IgM and IgG antibody levels of severe patients in the unvaccinated group were significantly higher than those in the normal, mild, and asymptomatic groups at 22-<29 days and 29-<36 days of hospitalization (F=17.694,15.116, 4.037, 4.115, all P < 0.05). Conclusion: IgM and IgG antibody levels in severe patients are more activated by immune defense during recovery. In the case of vaccination, IgM antibody can well reflect the whole course of SARS-CoV-2 infection.
ABSTRACT
Objective: To observe early laboratory indicators in peripheral blood of patients infected with SARSCoV- 2 Delta variant and the protective effects of COVID-19 vaccine on patients infected with SARS-CoV-2 Delta variant, in order to provide reference for epidemic prevention and control. Methods: Twenty-five Chengdu local confirmed nonsevere COVID-19 patients over 18 years old who were infected with COVID-19 caused by Delta variant in November 2021 were included as the research group, 22 cases of whom were vaccinated with COVID-19 vaccine before infection, and 3(2 cases over 80 years old)were unvaccinated. In addition, 71 non-severe COVID-19 patients at the age of over 18 years diagnosed in Chengdu from January 2020 to February 2020 were included as the control group. Peripheral blood was collected for laboratory examination in all cases on the first or second days after admission, and peripheral blood was collected for laboratory examination again in patients on day 4 to 8 after admission in the research group. Laboratory indicators included the blood routine, C-reactive protein, procalcitonin, liver function, myocardial enzyme profile, coagulation routine, T lymphocyte subsets, SARS-CoV-2 IgG antibody, and total antibody, etc. The first peripheral blood laboratory test results: of the two groups were compared to observe the protective effect of COVID-19 vaccine on patients infected with SARS-CoV- 2 Delta variant. Results Among the first time of laboratory indicators after admission, the lymphocyte count, lactate dehydrogenase, and D-dimer in the research group were all lower than those in the control group(all P < 0.05), and the procalcitonin and aspartate aminotransferase were higher than those in the control group(all P < 0.05). Among the 22 cases who had gotten vaccine before infection in the research group, there were 5 cases with positive result of SARS-CoV-2 IgG antibody in the first time of peripheral blood, 22 cases with positive result of SARS-CoV-2 IgG antibody in the second time of peripheral blood, and none of them became severe cases. During 3 unvaccinated cases, twice of the SARS-CoV-2 IgG antibody were both negative among the 2 cases over 80 years who had not vaccinated in the research group, then they became severe cases on day 6-8 during hospitalization, and the rest one had negative result of SARS-CoV-2 IgG antibody in the second time of peripheral blood. Among the 22 vaccinated cases in the research group, the lymphocyte count, CD4+T cell count, CD8+T cell count, SARS-CoV-2 specific antibodies in the second time peripheral blood were all higher than those in the first time of peripheral blood(all P < 0.05), and platelet count, hemoglobin, total protein, creatine kinase were all lower than those in the first time of peripheral blood(all P < 0.05). Conclusions: Lymphocyte count at early admission in COVID-19 patients infected with Delta variant may be lower than that infected with wild strain. COVID-19 vaccine can reduce the risk of infection of SARS-CoV-2 Delta variant by preventing the emergence of inflammatory storms and producing a large number of specific antibodies.
ABSTRACT
Objective To analyze IgG test results of serum SARS-CoV-2 antibody in people after booster vaccinations against SARS-CoV-2, and to provide a basis for the booster vaccination. Methods There were 314 healthy individuals who had been vaccinated with the COVID-19 vaccine. Depending on their inoculation situation, they were divided into three groups:the booster injection group(1 week to 2 months after booster vaccination)of 205 cases, <180 days after two doses group(<180 days after two doses of COVID-19 vaccine)of 49 cases, and >180 days after two doses group(>180 days after two doses of COVID-19 vaccine)of 60 cases. The positive rate of IgG in serum of the three groups was measured using the colloidal gold method. Results The serum COVID-19 antibody IgG positive rates were 83.9% in the booster injection group, 18.4% in the <180 days after two doses group, and 5.0% in the >180 days after two doses group, with statistically significant difference between any two groups(all P < 0.05). In the booster injection group, the serum COVID-19 antibody IgG positive rate was 85.2% in people who received a booster injection more than a month, while those who received a booster injection less than a month had a positive rate of 75.9%, and there was no significant difference between these two groups(P > 0.05). In the booster injection group, the positive rates of serum COVID-19 antibody IgG were 85.1% in males and 82.4% in females, with no significant difference(P > 0.05). In the booster injection group, people at the age of 18 and 50 had a positive serum COVID-19 antibody IgG rate of 86.0%, while those over 50 had a positive rate of 58.3%, and there was significant difference between them(P < 0.05). Conclusions Compared with two injections of the COVID-19 vaccine, the booster injection can significantly increase the positive rate of the antibody IgG of COVID-19, which results in a stronger immune response. There is a lower IgG positive rate of COVID-19 antibodies in those aged over 50 years following the booster dose of COVID-19 vaccine than in those aged 18- 50 years.
ABSTRACT
Objective: To compare the clinical manifestations, liver function, and antibody levels between Omicron variant infection patients vaccinated and not vaccinated with COVID-19 vaccine. Methods: Totally 430 convalescent COVID-19 patients infected with Omicron variant in Tianjin were selected, including 150 patients vaccinated with Corona Vaccine(Sinovac group), 185 patients vaccinated with BBIBP-CorV(Beijing biological group), 41 patients vaccinated with Ad5-nCoV vaccine(CanSino group), 16 patients vaccinated with Anhui Zhifei, Changchun Bio, Lanzhou Bio, Shandong Bio, other adenovirus vector vaccines or mixed vaccination(other group), and 38 unvaccinated patients(unvaccinated group). The clinical manifestations, liver function indexes [alanine aminotransferase(ALT), aspartate aminotransferase(AST), total bilirubin(TB), albumin(ALB), total protein(TP), lactate dehydrogenase(LDH)], and antibody levels(IgG, IgM)were compared retrospectively. Results: There was no statistical difference in the sex composition ratio among groups(P > 0.05). The age of the Beijing biological group was significantly lower than that of other groups, and the proportion of time less than 3 months from the last vaccination to admission in the Beijing biological group and CanSino group was significantly higher than that in the Sinovac group and other groups(all P < 0.01). A total of 110 children aged less than 16 years were enrolled, including 7, 88, 0, 1 and 14 cases in the Sinovac group, Beijing biological group, CanSino group, other group, and unvaccinated group, respectively. There were 6 asymptomatic cases, 13 moderate cases, 91 mild cases and 0 severe case. There was no significant difference in the abnormal rate of ALT between Beijing biological group and unvaccinated group(P > 0.05), but the abnormal rates of ALT were higher in the Sinovac group and CanSino group than in the unvaccinated group and Beijing biological group(all P < 0.05). The abnormal rate of AST in the unvaccinated group was higher than that in other groups(P < 0.05). There were no significant differences in AST, TP or TB among the groups(all P > 0.05). The levels of ALT were higher in the Sinovac group and CanSino group than in Beijing biological Group and unvaccinated group, the level of ALB in the unvaccinated group was lower than that in the other groups, and the level of LDH in the Beijing biological group was higher than those in the Sinovac group and CanSino group(both P < 0.05). The IgG and IgM antibody levels of the unvaccinated group were significantly lower than those of the Sinovac group, Beijing biological group and CanSino group(all P < 0.05). Conclusions: Omicron variant infection patients vaccinated with BBIBP-CorV are younger and have a higher proportion of mild conditions, which can protect the liver function of patients to a certain extent. Patients vaccinated with different COVID-19 vaccines can produce higher levels of IgG and IgM antibodies than the unvaccinated patients.
ABSTRACT
Background: COVID-19 has largely affected humans with high infection spread and mortality rates globally including India with no specific vaccine or therapy proven effective for its management as the immune response to COVID-19 is not well understood. Covishield has been largely distributed and administered in Indian subjects. However, its efficacy and safety are still unclear raising doubts. Aim: The present study aimed to assess the efficacy, safety, and immunogenicity of the Covishield vaccine in healthcare personnel in India. Methods: In 244 healthcare workers, SARS CoV2 IgG antibodies were assessed before and following the vaccination with two doses of Covishield given at 4 to 6 weeks apart. The efficacy of the vaccine and adverse effects after immunization were evaluated till two months after vaccination. The most common side-effect seen after the 1st dose was pain at the site of injection reported in 53.27% (n=130) study subjects followed by fever in 27.86% (n=68) study subjects, body ache in 22.95% (n=56) study subjects Results: Before vaccination, IgG was positive in 21.31% (n=52) study subjects and was negative in 78.68% (n=192) study subjects. Post-vaccination, IgG-positive status was seen in 69.67% (n=170) study subjects and was not seen in 30.32% (n=74) study subjects. In the infected group having 62 subjects, post-vaccination IgG positive was seen in 96.77% (n=60) study subjects and not seen in 3.22% (n=2) study subjects. In the uninfected group including the 182 subjects, post vaccination IgG positive was seen in 60.43% (n=110) study subjects and was not seen in 39.56% (n=72) study subjects respectively. After 2nd dose, the most common side-effect was pain at the site of injection seen in 24.59% (n=60) study subjects followed by headache in 12.29% (n=30) study subjects, fever in 7.37% (n=18) study subjects, body ache in 3.27% (n=8) participants, low backache and fatigue in 1.63% (n=4) study subjects each and local swelling in 0.81% (n=2) study subjects respectively. All the side effects had a non-significant difference except body ache which was significantly higher after 1st dose with p=0.02. Conclusion: Covishield vaccine has acceptable safety profile levels with increased seropositivity with more intervals in the two doses of the Covishield vaccine. Covishield does not prevent breakthrough infection. However, it can reduce the infection severity of COVID-19.
ABSTRACT
Non-SARS coronaviruses (HCoVs) contribute substantially to seasonal common colds. Their structural homology with SARS-CoV-2 suggests a possible cross-reactivity and cross-protection. The presence of IgG to the most common HCoVs (NL63, 229E, OC43, HKU1) in correlation with RBD-specific IgG and IgA, and the susceptibility to SARS-CoV-2 infection was evaluated in 48 individuals with recently diagnosed moderate SARS-CoV-2 infection (A, n=24) or intensive exposure to SARS-CoV-2 (B, n=24). Anti-S1 IgG for each of the four HCoVs, alongside with RBD-IgG and RBD-IgA were evaluated using ELISA (Creative Diagnostics, USA;Euroimmune, Germany). RBD-specific IgG and IgA were detected in 37% and 71% of group A (average levels 8.5 and 6.8) and 42% and 29% of group B (average levels 3.4 and 4.6 respectively, p < 0.05). IgG specific for NL63, 229E, and OC43 was present in 100.0%, and for HKU-1 - in 94% of tested samples (average index 7.4, 3.9, 4.1, and 2.6, respectively). The levels of IgG to NL63 and 229E did not differ significantly between the groups (7.6 vs.7.2;3.7 vs. 4.1, p > 0.05), nor did correlate with anti-SARS-CoV-2 response. HKU-1-specific IgG was significantly decreased in COVID-19 patients (A) as compared to SARS-CoV-2 resistant donors (B): 1.98vs.3.2, p < 0.01. Curiously, OC43-specific IgG was lower in the group with intensive exposure to SARS-CoV-2 (3.5vs.4.7, p < 0.01), and correlated with RBD-specific IgA (R=0.42, p < 0.05). IgG to seasonal coronaviruses is commonly detected, but only HKU-1-specific IgG was associated with resistance to SARS-CoV-2 infection. OC43-specific IgG may be induced simultaneously with RBD-specific IgA and interfere with SARS-CoV-2 neutralization.
ABSTRACT
This study was aimed at evaluating the changes in the antibody titers and neutralization ability before and after inoculation with an mRNA COVID-19 vaccine (Pfizer, USA) among healthcare professionals (HCPs) in Japan. A total of 221 HCPs were enrolled and their blood samples were collected at three time points: (1) before vaccination, (2) 3 weeks after the first dose, and (3) 3 weeks after the second dose. The titers of anti-SARS-CoV-2 Spike protein IgG antibody were measured in all the samples using VITROS-Anti-SARS-CoV-2 S1 Quant IgG Antibody (CLEIA, Ortho-Clinical Diagnostics, Inc.), and the surrogate Virus Neutralization Test (sVNT) (ELISA, GenScript, USA) was performed in the samples obtained after the vaccination. The anti-SARS-CoV-2 IgG titers were (1) median: 0.16;Interquartile (IQR): 0.10-0.27, (2) median: 250;IQR: 99.5-466 and (3) median: 2,400;IQR: 1,480-3,950, respectively, at the three time-points. Our study also revealed the relationship between the anti-SARS-CoV-2 IgG antibody titer and the antibody neutralization activity.
ABSTRACT
The aim of the work: To map the prevalence of antibodies against SARS-CoV-2 among employees of the Faculty Thomayer Hospital in Prague after the first wave of the covid-19 disease. A large number of people with proven covid-19 infection were treated and hospitalized in the first wave at the Thomayer University Hospital. Material and methods: Voluntary study based on questionnaire survey and determination of total antibodies (ECLIA, Roche) and individual classes of immunoglobulins (ELISA IgG and IgA, Euroimmun).
ABSTRACT
Aim: The presence of neutralizing antibodies (NAbs) is an indicator of protective immunity for most viral infections. This study investigated the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibodies NAbs (IgM & IgG) following vaccination with three common potential vaccines (Pfizer, AstraZeneca and Sino pharm), in Nasiriya city /south of Iraq. Methods. From September 2021 to April 2022.158 participants who had completed COVID-19 vaccination (50 persons for each) were recruited and tested using Covid-19 neutralizing antibody kits, for NAbs evaluation. Results. Majority of the participants were 21-40 years old of age. NAbs were observed in 100% of enrolled individuals (vaccinated or not) but with significant difference in the IgM and IgG titers in correlate to the vaccine type, but there weren't with other demographic factors effect. Nine days after second vaccine dose, spike protein neutralizing antibody levels were two-fold higher of IgM and 5-fold higher of IgG, exceeding titers of non-vaccinated SARS-CoV-2-naive control. Pfizer vaccine type against COVID-19 gave the highest IgM and IgG titers during the 6 months' trial, with the lowest declining rate. AstraZeneca vaccine type provided an intermediate IgM and IgG titer with a rapid declining rate, while Sino pharm vaccine offered a low IgM and IgG titers with slowly decreasing rate with time.
ABSTRACT
To evaluate the effect of colloidal gold immunochromatographic assay (GCIA) combined with chemiluminescent immunoassay (CLIA) in reducing the false positive of antibodies against severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Thirty-three serum samples from 19 patients with SARS-CoV-2 infection at different times, and 55 serum samples from 55 patients not infected with SARS-CoV-2. but infected instead with other pathogens or suffering from autoimmune diseases were collected from the Affiliated Hospital of North Sichuan Medical College and Nanchong Central Hospital from 22 January to 5 March 2020. Serum IgM and IgG against SARS-CoV-2 were detected by GICA and CLIA respectively, and the results were analyzed. The sensitivity of GCIA for detection of IgM and IgG against SARS - CoV - 2 was 100.0% and 94.74%. respectively, values that were similar with those for CLIA (92.86% and 100.0%) (P = 1.000). The specificity of GCIA for IgM and IgG against SARS-CoV-2 was 70.91% and 74.55% respectively, which was significantly lower than that of CLIA (98.18% and 89.09%) (P < 0.01). The results of IgM and IgG against SARS-CoV-2 detected by the two methods were consistent (P=0.000) . and their Kappa was 0.434 and 0.406. respectively. Analyses of ROC curves showed that the AUC of IgM and IgG against SARS-CoV-2 detected by GCIA was 0.855 and 0.846. respectively, which was significantly lower than that of CLIA (0.955 and 0.945, respectively) (PC0.05). The sensitivity of combined detection of IgM and IgG against SARS -CoV-2 was 92.86% and 94.74%. and the specificity was 100.0% and 100.0%, respectively. Analyses of ROC curves showed that the AUC of combined detection of IgM and IgG against SARS-CoV-2 was 0.964 and 0.974. respectively, which was higher titan that of each method alone. GCIA combined with CLIA can improve the specificity of detection of IgM and IgG against SARS-CoV-2, which may merit clinical application.
ABSTRACT
This study aimed to evaluate the application and diagnostic efficacy of two different colloidal gold kits for the detection of 2019-nCoV immunoglobulin M antibody (anti-IgM) and immunoglobulin G antibody (anti-IgG) in Beijing, a low endemic area, and to guide the rational clinical application. The sera of 29 patients with confirmed novel coronavirus pneumonia (COVID-19) and 19 411 patients from the non-infected screening population were selected to evaluate the sensitivity, specificity and false-positive rate of the 2019-nCoV antibody test kits from Zhuhai Lizhu and Tangshan Innotek using colloidal gold immunochromatography. The sensitivity of Inotec 2019-nCoV was slightly higher than that of Lizhu 2019-nCoV, with a sensitivity of 58.62% and 55.17%, respectively;the specimen collection time of the all-negative group was significantly less than that of the antibody-positive group (P < 0.05);the false-positive rate of the two reagents in the low-prevalence area was 0.16%, and the false-positive rate of 2019-nCoV IgG was higher in Inotec than in Lizhu. The false positive rate for 2019-nCoV IgM was significantly higher than that for IgG for the same brand (Inotec ?2=14.756 09, P=0.000 0;Lizhu ?2=27.492 62, P=0.000). Conclusion The 2019-nCoV antibody test is rapid, simple and easy to perform, with high specificity, and can be used as a rapid screening indicator for new crowns;the specificity, correctness and negative predictive value of the two kits are good, and the application of the other kit for retesting when a positive result occurs can reduce the false positive rate of informing the clinic;the application and analysis of positive reports of new crown antibodies should be combined with the endemic area and clinical comprehensive judgment.
ABSTRACT
Objective: To understand the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) specific IgM, IgC and IgA responses in corona Virus disease 2019(COVID-19) patients. Method: The SARS-CoV-2-specific IgM and IgG levels were determined by the enzyme-linked immunosorbent assay while IgA 1evels were detected by the chemiluminescence immune detection systems.
ABSTRACT
This study presents the results of the examination of potential donors of blood and its components for immunoglobulins M and G to patients with coronavirus disease 2019 (COVID-19) living in St. Petersburg. A total of 6782 people aged 18-24 years were evaluated, which accounted for 2.07% of the region's population (326 760 people) of this age group. The study was carried out in the spring and autumn of 2020. A negative result (absence of antibodies) was obtained in 93.5% of the participants. The rates of immunoglobulins M and M + G were 0.58% and 4.18%, respectively, in the spring and autumn. Moreover, the number of participants who had immunoglobulins M and G + M in the autumn period was four times higher than the indicators of the spring period, which indicated greater infection activities in the population during this period. This is most likely due to the active movement of the population in the summer. When comparing the rates of COVID-19 infection and the frequency of occurrence in donors of the same age, markers of human immunodeficiency virus 1 and 2 and hepatitis B and C in 2020 (0.024, 0.012 and 0.13%, respectively) indicate the urgency of the problem of donor selection during blood services, especially during a difficult epidemiological situation because of COVID-19. Along with organizational measures for the selection of donors (e.g., attracting individuals from organized groups in which there are no signs of an unfavorable epidemiological situation to donation), mandatory testing of potential donors for immunoglobulins M and G should be considered.